GRDN · NYSE · Healthcare
Guardian Pharmacy Services, Inc. (GRDN) — Rank #38 by gross profitability (GP/assets 0.66) · ROE 19.1% · Piotroski F-Score N/A.
As-of 2026-10-30 · CIK 0001802255 · all metrics point-in-time as of the filing date.
About
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States.
Show moreShow less
The company's individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes. Its Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; GuardianShield Programs for LTCFs; Order Entry QA Analyzer, which utilizes real-time rules- engine technology to examine prescriptions and detect omissions and/or errors before they become a customer service problem; and Medication Spend Analyzer to break down the monthly drug spending for each of the LTCFs. Guardian Pharmacy Services, Inc.
was founded in 2003 and is headquartered in Atlanta, Georgia.
- Industry
- Medical Care Facilities
- Sector
- Healthcare
- State
- GA
- Filer Category
- Accelerated filer
- Fiscal Year End
- December 31
- Website
- guardianpharmacy.com
Company Snapshot
P/E and reverse DCF are the primary valuation lenses at this stage.
Market Cap
—
P/E (annual)
—
P/S (annual)
—
P/B
—
P/OCF (annual)
—
Shareholder Yield
—
Employees
3,600
Industry
Medical Care Facilities
Exchange
NYSE
10/10
Flags passed
GRDN passes 10/10 quality flags
- PASSGross margin holding
- PASSFCF not negative from investment
- PASSDisclosure consistent
- PASSRevenue not declining
- PASSOperating margin holding
- PASSFree cash flow intact
- PASSPasses safety gate
- PASSBalance sheet stable
- PASSNo competitive retreat
- PASSSBC not compressing margin
No data Dilution · Valuation — not counted as a pass.
A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
1/1 passOperating margin expansion and free cash flow are the primary reads at this stage.
Profitability
Does it make money well?
No warning flags · GP/assets 0.66
Gross profitability (GP / assets)
0.66
Primary signal (Novy-Marx).
6th of 11 SIC 59 peers
Return on equity
19.1%
Gross margin
20.2%
9th of 11 SIC 59 peers
Revenue growth (YoY)
17.9%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2024 | 2025 | |
|---|---|---|
| Revenue vs COGS | ||
| Revenue vs OpEx | ||
| Op. Income vs Revenue |
Cash Flow Health
Is the cash real?
No warning flags · FCF 76% above net income
Free cash flow
$86.84M
Operating cash flow minus capex.
Positive free cash flow
FCF vs net income
76.4%
(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.
FCF not below net income
Fails when free cash flow is below net income (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
1.0%
Stock-based comp intensity.
Balance Sheet Strength
Can it survive a storm?
No warning flags · net cash $89.81M
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
0.72
2nd of 10 SIC 59 peers (best = lowest)
Current ratio
1.65×
5th of 11 SIC 59 peers
Quick ratio
1.26×
Net cash
$89.81M
Cash & equivalents minus total debt.
Piotroski F-Score
N/A
Only 8/9 components determinable.
Valuation
Is the price reasonable?
No data
Capital allocation quality
Composite score
2.0 / 5
Lifecycle Phase History
Price History
Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports